These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 25720625)
1. Stent selection and antiplatelet therapy duration: one size does not fit all. Kandzari DE J Am Coll Cardiol; 2015 Mar; 65(8):816-819. PubMed ID: 25720625 [No Abstract] [Full Text] [Related]
2. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. Valgimigli M; Patialiakas A; Thury A; McFadden E; Colangelo S; Campo G; Tebaldi M; Ungi I; Tondi S; Roffi M; Menozzi A; de Cesare N; Garbo R; Meliga E; Testa L; Gabriel HM; Airoldi F; Ferlini M; Liistro F; Dellavalle A; Vranckx P; Briguori C; J Am Coll Cardiol; 2015 Mar; 65(8):805-815. PubMed ID: 25720624 [TBL] [Abstract][Full Text] [Related]
3. Dual Antiplatelet Therapy Duration Following Coronary Stenting. [Corrected]. Yeh RW; Mauri L; Kereiakes DJ J Am Coll Cardiol; 2015 Mar; 65(8):787-790. PubMed ID: 25720621 [No Abstract] [Full Text] [Related]
4. Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORT OUT III study): a multicentre, open-label, randomised superiority trial. Maeng M; Tilsted HH; Jensen LO; Krusell LR; Kaltoft A; Kelbæk H; Villadsen AB; Ravkilde J; Hansen KN; Christiansen EH; Aarøe J; Jensen JS; Kristensen SD; Bøtker HE; Thuesen L; Madsen M; Thayssen P; Sørensen HT; Lassen JF Lancet; 2014 Jun; 383(9934):2047-2056. PubMed ID: 24631162 [TBL] [Abstract][Full Text] [Related]
5. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial. Gilard M; Barragan P; Noryani AAL; Noor HA; Majwal T; Hovasse T; Castellant P; Schneeberger M; Maillard L; Bressolette E; Wojcik J; Delarche N; Blanchard D; Jouve B; Ormezzano O; Paganelli F; Levy G; Sainsous J; Carrie D; Furber A; Berland J; Darremont O; Le Breton H; Lyuycx-Bore A; Gommeaux A; Cassat C; Kermarrec A; Cazaux P; Druelles P; Dauphin R; Armengaud J; Dupouy P; Champagnac D; Ohlmann P; Endresen K; Benamer H; Kiss RG; Ungi I; Boschat J; Morice MC J Am Coll Cardiol; 2015 Mar; 65(8):777-786. PubMed ID: 25461690 [TBL] [Abstract][Full Text] [Related]
6. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY). Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G; JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420 [TBL] [Abstract][Full Text] [Related]
7. Randomized Angiographic and Intravascular Ultrasound Comparison of Dual-Antiplatelet Therapy vs Triple-Antiplatelet Therapy to Reduce Neointimal Tissue Proliferation in Diabetic Patients. Zuliani Mauro MF; Mangione JA; Costa JR; Costa R; Piva E Mattos LA; Staico R; Feres F; Siqueira D; Sousa A; Abizaid A J Invasive Cardiol; 2017 Mar; 29(3):76-81. PubMed ID: 28255102 [TBL] [Abstract][Full Text] [Related]
8. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. Feres F; Costa RA; Abizaid A; Leon MB; Marin-Neto JA; Botelho RV; King SB; Negoita M; Liu M; de Paula JE; Mangione JA; Meireles GX; Castello HJ; Nicolela EL; Perin MA; Devito FS; Labrunie A; Salvadori D; Gusmão M; Staico R; Costa JR; de Castro JP; Abizaid AS; Bhatt DL; JAMA; 2013 Dec; 310(23):2510-22. PubMed ID: 24177257 [TBL] [Abstract][Full Text] [Related]
9. Long-term comparative analysis from an all-comer cohort of coronary patients treated using first- and second-generation drug-eluting stents. Codner P; Bental T; Assali A; Vaknin-Assa H; Lev E; Kornowski R J Invasive Cardiol; 2014 Aug; 26(8):378-84. PubMed ID: 25091097 [TBL] [Abstract][Full Text] [Related]
10. Bioresorbable vascular scaffolds in daily clinical practice: is the essential really invisible to the eyes? Abizaid A; Costa JR; Gibson CM J Am Coll Cardiol; 2015 Mar; 65(8):802-804. PubMed ID: 25720623 [No Abstract] [Full Text] [Related]
11. Angiographic patterns of restenosis with 2nd generation drug-eluting stent: comparative analysis from a 10-year single-center experience . Lee S; Yoon CH; Oh IY; Suh JW; Cho YS; Cho GY; Chae IH; Choi DJ; Youn TJ Int Heart J; 2015; 56(1):6-12. PubMed ID: 25503656 [TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) trial. Lee SW; Park SW; Kim YH; Yun SC; Park DW; Lee CW; Kang SJ; Park SJ; Lee JH; Choi SW; Seong IW; Lee NH; Cho YH; Shin WY; Lee SJ; Lee SW; Hyon MS; Bang DW; Choi YJ; Kim HS; Lee BK; Lee K; Park HK; Park CB; Lee SG; Kim MK; Park KH; Park WJ; J Am Coll Cardiol; 2011 Mar; 57(11):1264-70. PubMed ID: 21392640 [TBL] [Abstract][Full Text] [Related]
13. Stent fracture and restenosis after zotarolimus-eluting stent implantation. Park JS; Cho IH; Kim YJ Int J Cardiol; 2011 Mar; 147(2):e29-31. PubMed ID: 19203806 [TBL] [Abstract][Full Text] [Related]
14. Safety of 6-month duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes: Rationale and design of the Smart Angioplasty Research Team-safety of 6-month duration of Dual Antiplatelet Therapy after percutaneous coronary intervention in patients with acute coronary syndromes (SMART-DATE) prospective multicenter randomized trial. Lee JM; Cho DK; Hahn JY; Song YB; Park TK; Oh JH; Lee JB; Doh JH; Kim SH; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC Am Heart J; 2016 Dec; 182():1-8. PubMed ID: 27914488 [TBL] [Abstract][Full Text] [Related]
15. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds. Puricel S; Arroyo D; Corpataux N; Baeriswyl G; Lehmann S; Kallinikou Z; Muller O; Allard L; Stauffer JC; Togni M; Goy JJ; Cook S J Am Coll Cardiol; 2015 Mar; 65(8):791-801. PubMed ID: 25720622 [TBL] [Abstract][Full Text] [Related]
16. Polymer-free sirolimus- and probucol-eluting versus new generation zotarolimus-eluting stents in coronary artery disease: the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting versus Zotarolimus-eluting Stents (ISAR-TEST 5) trial. Massberg S; Byrne RA; Kastrati A; Schulz S; Pache J; Hausleiter J; Ibrahim T; Fusaro M; Ott I; Schömig A; Laugwitz KL; Mehilli J; Circulation; 2011 Aug; 124(5):624-32. PubMed ID: 21768546 [TBL] [Abstract][Full Text] [Related]